石药集团：强效醛固酮合成酶抑制剂( SYH2072片)在美国获临床试验批准

Core Viewpoint - The announcement highlights that the pharmaceutical company has received approval from the U.S. Food and Drug Administration (FDA) for its novel Class 1 chemical drug, SYH2072 tablets, which are a potent aldosterone synthase inhibitor, allowing for clinical trials in the U.S. [1] Group 1: Product Approval and Clinical Trials - The product has also been approved by the National Medical Products Administration (NMPA) of China for clinical trials, expected to commence by December 2025 [1] - SYH2072 is designed to selectively inhibit aldosterone synthase, effectively lowering plasma aldosterone levels without affecting cortisol levels [1] Group 2: Clinical Indications and Research Findings - The approved clinical indications for SYH2072 include uncontrolled hypertension and resistant hypertension [1] - Preclinical studies indicate that the product significantly reduces plasma aldosterone levels and blood pressure in hypertensive models in a dose-dependent manner [1] Group 3: Drug Potential and Market Value - The product exhibits favorable pharmacokinetic (PK) properties and safety, positioning it as a potential best-in-class drug [1] - Given the broad clinical demand for aldosterone synthase inhibitors, SYH2072 holds high clinical development value and is expected to provide new treatment options for patients with uncontrolled and resistant hypertension [1]